^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Allocetra (HLA-matched donor mononuclear enriched leukocytes)

    i
    Other names: leukocyte stem cell therapy, autologous apoptotic cell-based therapy, non-HLA-matched allogeneic peripheral blood mononuclear cells
    Associations

    News

    Trials
    Company:
    Enlivex Therap
    Drug class:
    Immunomodulator
    Related drugs:
    Associations

    News

    Trials
    1m
    ENX-CL-06-001: Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis (clinicaltrials.gov)
    P1, N=6, Recruiting, Enlivex Therapeutics Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    4ms
    Apoptotic Cell-Based Therapy for the Modification of the Inflammatory Response to Hemorrhagic Shock. (PubMed, Mil Med)
    In a pressure-control hemorrhagic shock model in rats, apoptotic cell infusion showed preliminary signs of a uniform attenuated cytokine response. Apoptotic cell-based therapies might serve as a novel immunomodulatory therapy for hemorrhagic shock.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    5ms
    Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Enlivex Therapeutics Ltd.
    New P1 trial
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    6ms
    Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint (clinicaltrials.gov)
    P1/2, N=46, Recruiting, Kaplan Medical Center
    New P1/2 trial
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    8ms
    Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis (clinicaltrials.gov)
    P1/2, N=9, Terminated, Enlivex Therapeutics RDO Ltd. | Trial completion date: Sep 2024 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Mar 2024; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    8ms
    A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy (clinicaltrials.gov)
    P1/2, N=14, Terminated, Enlivex Therapeutics RDO Ltd. | N=72 --> 14 | Trial completion date: Dec 2024 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Apr 2024; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Tevimbra (tislelizumab-jsgr) • Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    9ms
    A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Enlivex Therapeutics Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2024 --> Dec 2024
    Enrollment closed • Trial primary completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    9ms
    A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) (clinicaltrials.gov)
    P2, N=12, Terminated, Enlivex Therapeutics Ltd. | Phase classification: P2b --> P2 | Trial completion date: Sep 2023 --> Mar 2024 | Active, not recruiting --> Terminated; strategic reprioritization
    Phase classification • Trial completion date • Trial termination
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    11ms
    ENX-CL-05-001: Study of Intra-articular Allocetra in Knee Osteoarthritis (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Enlivex Therapeutics Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    11ms
    A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, Enlivex Therapeutics Ltd.
    New P1/2 trial
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    11ms
    Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety (clinicaltrials.gov)
    P1, N=12, Recruiting, Amir Oron
    New P1 trial
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    over1year
    Allocetra-OTS (apoptotic cells) Downregulate IL-6, IL-5, and IP-10, Associated with Severe Cytokine Release Syndrome (CRS), and have a Synergistic Anti-Cancer Effect with chimeric antigen receptor (CAR)-T against Peritoneal Solid Tumor (ESMO 2023)
    No abstract available
    IL6 (Interleukin 6) • IL5 (Interleukin 5)
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    over1year
    A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy (clinicaltrials.gov)
    P1/2, N=72, Recruiting, Enlivex Therapeutics RDO Ltd. | N=48 --> 72 | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Tevimbra (tislelizumab-jsgr) • Allocetra (HLA-matched donor mononuclear enriched leukocytes)